SCHEMBL743914

SCHEMBL743914

CN1C2CCC1CC(Nc1ccc(-c3ccc4cc[nH]c4c3)nc1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.47
CHRNA7 P36544 6/20 0.47
KAT2B Q92831 1/20 0.41
PIP4K2A P48426 1/20 0.39
PIP4K2B P78356 1/20 0.39
BRD4 O60885 2/20 0.39
ATAD2 Q6PL18 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.37
MTOR P42345 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GHSR Q92847 1/20 0.36
ROCK2 O75116 2/20 0.36
ARHGDIA P52565 2/20 0.36
ROCK1 Q13464 2/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743913 1.00 KCNH2 (0.47) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
SCHEMBL745267 0.93 CHRNA7 (0.48) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
SCHEMBL745268 0.93 CHRNA7 (0.48) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
Hydrochloric Acid SCHEMBL746659 0.92 CHRNA7 (0.48) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
Hydrochloric Acid SCHEMBL746658 0.92 CHRNA7 (0.48) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL989901 0.91 KCNH2 (0.41) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL989899 0.91 KCNH2 (0.41) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B
SCHEMBL746411 0.83 ROCK2 (0.52) KCNH2CHRNA7MTORCYP3A4ROCK2
SCHEMBL746412 0.83 ROCK2 (0.52) KCNH2CHRNA7MTORCYP3A4ROCK2
SCHEMBL743838 0.83 PIP4K2A (0.48) KCNH2CHRNA7KAT2BPIP4K2APIP4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940762-B2 Methods for treating pain ABBVIE INC. (US) 2015-01-27 US claimed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP claimed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP claimed
US-20110178121-A1 Methods for Treating Pain ABBOTT LABORATORIES (US) 2011-07-21 US claimed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US claimed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US claimed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US claimed
US-8940762-B2 Methods for treating pain ABBVIE INC. (US) 2015-01-27 US disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-20110178121-A1 Methods for Treating Pain ABBOTT LABORATORIES (US) 2011-07-21 US disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 KCNH2 708/4885CHRNA7 2776/4885KAT2B 609/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 KCNH2 708/4885CHRNA7 2776/4885KAT2B 609/4885
US-20110178121-A1 Methods for Treating Pain CHRNA7, CHRNA3, CHRNA5 KCNH2 183/4885CHRNA7 1/4885KAT2B 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.